Aldea Pharmaceuticals

Aldea is developing novel enzyme activators to enhance the removal of toxic aldehydes, including those associated with the common flushing response to alcohol in persons of East Asian descent.

Private  |  Palo Alto, CA
Altheos

Altheos is a biopharmaceutical company focused on the development of promising novel small molecule drugs for the treatment of glaucoma.

Private  |  South San Francisco, CA
Amicus Therapeutics

Amicus is pioneering next-generation oral therapies for the management of human genetic diseases.

Public (FOLD)  |  Cranbury, NJ
BiPar Sciences, Inc.

BiPar is developing a potential new class of tumor-selective drugs designed to meet the unmet needs of cancer patients.

Acquired by Sanofi (EURONEXT: SAN) (NYSE: SNY)
Calixa Therapeutics

Calixa is developing hospital-based antibiotics to treat infections resulting from resistant strains of bacteria.

Acquired by Cubist Pharmaceuticals
Cell Pathways

Cell Pathways is a development-stage pharmaceutical company focused on novel medications to treat and prevent cancer and certain autoimmune diseases.

Public. Acquired by OSI Pharmaceuticals (OSIP)
Centocor

Centocor revolutionized the science of immunology and has been a leader in the field of cancer and immune-disorders for over 20 years.

Public (CNTO)  |  Malvern, PA
Cerexa

Cerexa is an innovative biopharmaceutical company focused on developing therapies for the treatment of serious and life–threatening infections.

Acquired by Forest Labs (FRX)
Chimerix

Chimerix is developing orally bioavailable antiviral therapies for unmet medical needs in immunocompromised patient populations, including transplant and oncology, HIV and HBV.

Private  |  Durham, NC
Civitas Therapeutics, Inc

Civitas is focused on developing pulmonary delivery therapies uniquely able to deliver large and precise doses via a simple inhalational device to address significant unmet need medical needs. The company’s lead program is for patients with Parkinson’s disease.

Private  |  Chelsea, MA
CombinatoRx

CombinatoRx is pioneering the new field of synergistic combination pharmaceuticals to provide a renewable and previously untapped source of novel drug candidates.

Public (CRXX)  |  Boston, MA
Dermira

Dermira is developing topical treatments for moderate to severe acne.

Private  |  Redwood City, CA
Durata Therapeutics, Inc.

Durata is a biopharmaceutical company pursuing late-stage clinical development of novel antibiotic programs.

Private  |  New York, NY
Elevation Pharmaceuticals

Elevation Pharmaceuticals is focused on the development of new aerosol therapies for the treatment of COPD (chronic obstructive pulmonary disease).

Private  |  San Diego, CA
Eon Labs

Eon Lab is a drug manufacturer that develops, manufactures, and markets a broad range of generic pharmaceutical products.

Public. Acquired by Novartis (NVS)
Esperion Therapeutics

Esperion is a biopharmaceutical company focused on the discovery and development of therapies for the treatment of cardiovascular disease.

Public. Acquired by Pfizer (PFE)
Genaissance Pharmaceuticals

Personalized medicine through population genomics and informatics.

Public. Acquired by Clinical Data (CLDA)
GenVec

GenVec develops gene therapy products.

Public (GNVC)  |  Gaithersburg, MD
Kalidex Pharmaceuticals, Inc.

Kalidex is developing next-generation, broad-spectrum antibiotics for the treatment of serious infections.

Private  |  Menlo Park, CA
Liquidia Technologies

Liquidia Technologies Inc. is a nanotechnology company that designs and manufactures precisely engineered particles and films for a variety of life and material science applications.

Private  |  Research Triangle Park, NC
Marinus Pharmaceuticals

Marinus is creating a new class of neurologic drugs that may revolutionize the treatment of epilepsy in women and infants.

Private  |  Branford, CT
Matrix Pharmaceutical

Matrix Pharmaceutical develops novel local and systemic cancer treatments that may improve or extend the lives of people living with cancer.

Public (MATX)
OraPharma

OraPharma is a specialty pharmaceutical company focused therapeutics for oral health.

Public. Acquired by Johnson & Johnson (JNJ)
Peninsula Pharmaceuticals

Peninsula Pharmaceuticals is developing new antibiotic medications to treat life-threatening infections.

Acquired by Johnson & Johnson (JNJ)
Phylogix

Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.

Private  |  Waltham, MA
Pozen

Pozen is a pharmaceutical company developing therapeutic advancements for treatment of acute migraine.

Public (POZN)
Praecis Pharmaceuticals

Praecis Pharmaceuticals is a biopharmaceutical company focused on Peptide-based therapeutics that have the potential to address unmet medical needs or improve existing therapies.

Public. Acquired by GlaxoSmithKline (GSK)
Sopherion

Sopherion is a therapeutics platform company initially focused on cancer.

Private  |  Princeton, NJ
Theraclone Sciences

Theraclone Sciences harnesses the power of the human immune system to treat cancer and infectious diseases.

Private  |  Seattle, WA
Tobira Therapeutics, Inc

Tobira develops novel drugs to help in the treatment of HIV and AIDS.

Private  |  Manalapan, NJ
VaxInnate

VaxInnate invents vaccines that can be rapidly tailored to treat influenza and major pandemic illnesses.

Private  |  Cranbury, NJ

Meet Specializing Partners

Brent Ahrens
Stephen Bloch
Peter Farina
Wende Hutton
Seth Rudnick
Tim Shannon

News

May 16, 2012
Elevation boasts 'gold standard' IIb data for COPD therapy

May 8, 2012
Ustream, Booyah Co-founders Team Up On Stealth Startup With $1.5M From Greylock, Kevin Rose & More

April 2, 2012
VaxInnate Names Wayne Pisano as its New CEO

March 22, 2012
Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

March 15, 2012
Hagan bill could speed approval process for drugs (Chimerix News)

February 13, 2012
Altheos initiates phase IIa trial of ROCK inhibitor compounds, ATS907  

February 9, 2012
Altheos grabs $12.5M more, launches glaucoma trial

February 6, 2012
Transplant antiviral strong in phase 2; Chimerix plans phase 3 start this year

January 30, 2012
Point, Click, Shoot-Connect! The Michael J. Fox Foundation Connects Parkinson’s Patients With Researchers (Civitas)

January 23, 2012
Dermira: Success is skin deep (BioCentury)

January 16, 2012
The Expanding Vaccine Market (Liquidia News)

January 9, 2012
Canaan Partners Closes $600 Million Fund

January 6, 2012
Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson's Disease

January 6, 2012
Civitas Charts Positive Data on Inhaled Parkinson’s Drug

January 4, 2012
Elevation Pharma raises $30M

December 31, 2011
Closed in 2008, Chelsea company makes comeback (Civitas Therapeutics)

December 21, 2011
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise in Open-Label Extension Study

December 19, 2011
VaxInnate Licenses Recombinant Flu Vaccines to CJ CheilJedang Corporation of South Korea

December 13, 2011
Joseph DeSimone at TEDMED 2011 (Liquidia)

December 13, 2011
Liquidia Technologies Announces Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine

December 6, 2011
Theraclone Sciences Announces Appointment of Clifford Stocks as CEO

December 6, 2011
Theraclone Names Cliff Stocks, Vet of Icos & Calistoga, as New CEO

November 29, 2011
Civitas Therapeutics Announces Award of Michael J. Fox Foundation Grant and Lead Drug Candidate for Parkinson’s Disease

November 29, 2011
Alkermes Spinoff, Civitas, Gets Michael J. Fox Support for Inhalable Parkinson’s Drug